Lyme disease Pipeline Report: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Key Companies – GSK plc., Pfizer, Inc., Novartis AG, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc., ChartwellPharma, and Almirall, LLC., CyanVac, Flightpath Biosciences, Inc, Cortene Inc., Valneva SE, Tarsus Pharmaceuticals, Inc,

DelveInsight’s ‘Lyme disease Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Lyme disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Lyme disease pipeline domain.

Lyme disease Overview

Lyme disease is the most common vector-borne disease caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. Lyme disease affects both humans and animals. Diagnosing Lyme disease is often difficult as many of the symptoms are similar to other conditions. The most accurate way to detect Lyme disease is with a two-stage blood test.

Some of the key takeaways from the Lyme disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Lyme disease treatment therapies with a considerable amount of success over the years. Lyme disease Key players such as – GSK plc., Pfizer, Inc., Novartis AG, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc., ChartwellPharma, and Almirall, LLC., CyanVac, Flightpath Biosciences, Inc, Cortene Inc., Valneva SE, Tarsus Pharmaceuticals, Inc , and others, are developing therapies for the Lyme disease treatment
• Lyme disease Emerging therapies such as – CT38, TP-05, BLB 400, FP-100, VLA15 , and others are expected to have a significant impact on the Lyme disease market in the coming years.
• In August 2022, Valneva initiated a Phase III, multicenter, placebo-controlled, randomized, observer-blinded trial to evaluate the efficacy, safety, tolerability, immunogenicity, and lot consistency of a 6-valent OSPA-based Lyme disease vaccine in healthy participants ≥5 years of age.
• In June 2022, Valneva SE and Pfizer Inc. announced that they have entered into an Equity Subscription Agreement and
• have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15.
• In December 2022, Valneva initiated Phase III, randomized, placebo-controlled, observer-blinded trial to evaluate the safety of a 6-valent OSPA-based lyme disease vaccine (VLA 15) in healthy children 5 through 17 years of age.

Discover more about the emerging Lyme disease drugs @ Lyme disease Treatment Drugs

Emerging Lyme disease Drugs Under Different Phases of Clinical Development Include:

• CT38: Cortene Inc.
• TP-05: Tarsus Pharmaceuticals, Inc
• BLB 400: CyanVac
• FP-100: Flightpath Biosciences, Inc
• VLA15: Valneva SE
• NCT05477524: Valneva SE

Lyme disease Pipeline Analysis:

The Lyme disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the Lyme disease treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lyme disease Treatment.
• Lyme disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Lyme disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lyme disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Lyme disease Market Drivers

• Increasing lyme disease prevalence
• Development in studies on the Lyme disease treatment

Lyme disease Market Barriers

• Lack of Lyme disease pipeline therapies
• Risk for significant long term health consequences.

Find out more about the Lyme disease treatment options in development @ Lyme disease Clinical Trials

Scope of Lyme disease Pipeline Drug Insight

• Coverage: Global
• Key Lyme disease Companies: GSK plc., Pfizer, Inc., Novartis AG, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc., ChartwellPharma, and Almirall, LLC., CyanVac, Flightpath Biosciences, Inc, Cortene Inc., Valneva SE, Tarsus Pharmaceuticals, Inc, and others
• Key Lyme disease Therapies:CT38, TP-05, BLB 400, FP-100, VLA15 , and others
• Lyme disease Therapeutic Assessment: Lyme disease current marketed and Lyme disease emerging therapies
• Lyme disease Market Dynamics: Lyme disease market drivers and Lyme disease market barriers

Table of Contents

1. Introduction
2. Executive Summary
3. Lyme disease Overview
4. Lyme disease Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Lyme disease Therapeutic Assessment
11. Lyme disease Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Lyme disease Unmet Needs
14. Lyme disease Market Drivers and Lyme disease Market Barriers
15. Appendix
16. About DelveInsight

Trending Reports by DelveInsight:

· Asthma Diagnostic Devices Market
· Chronic Obstructive Pulmonary Disease Treatment Devices Market
· Airway Management Devices Market
· Cough Assist Devices Market
· Pulse Oximeters Market
· Hemodialysis Catheter Devices Market
· Chronic Spontaneous Urticaria Market
· Gender Dysphoria Market
· Germany Healthcare Outlook
· Biopsy Devices Pipeline Insight
· Bacterial Conjunctivitis Market
· Infliximab Biosimilar Insight
· Eosinophilic Asthma Market
· Cushing Syndrome Market
· Functional Dyspepsia Market
· Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Contact Us

Navdha Goel
info@delveinsight.com
+1(919)321-6187